Articles tagged with Ovarian Cancer
Researchers discovered a mechanism used by ovarian tumors to cripple immune cells by blocking the energy supply T cells depend on. The discovery points toward a promising new immunotherapy approach for treating ovarian cancer.
The researchers aim to establish targets for the vaccine by identifying proteins on the surface of early-stage ovarian cancer cells recognized by the immune system. If successful, clinical trials will begin to test the vaccine's effectiveness in preventing ovarian cancer, potentially offering a solution for women at high risk.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A blood test combining AI, cell-free DNA, and protein biomarkers shows high accuracy in detecting ovarian cancer. The test distinguishes between benign growths and cancerous tumors, offering a potential affordable screening method for widespread use.
Researchers identified over 3,000 harmful genetic changes in the RAD51C gene that increase ovarian cancer risk six-fold and breast cancer risk four-fold. These findings can help doctors and diagnostic laboratory scientists better assess cancer risk and provide more personalized care.
A recent study found that Chinese patients with ovarian cancer often carry a specific variant of the RAD51D gene, which can promote tumor growth. The variant also makes these patients more sensitive to PARP inhibitors, leading to a favorable prognosis and potential new treatment methods.
Researchers analyzed data from 1741 women diagnosed with high-grade serous ovarian cancer and found that symptom-triggered testing can lead to diagnosis of low-disease spread cases. In most cases, complete surgical removal of the cancerous tissue was possible, challenging the assumption that symptoms always signal advanced disease.
Researchers found that symptom-triggered testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected. The UK's protocol for picking up early-stage disease is an effective way to diagnose even early-stage ovarian cancer, with complete surgical removal possible in more than three quarters of women.
A study by the University of Gothenburg finds that removing Fallopian tubes during laparoscopic sterilization results in marginally more surgical complications than cutting them. The procedure may help protect against future ovarian cancer, a serious disease with limited early symptoms.
Researchers found that abnormal results from routine blood tests were linked to a higher risk of being diagnosed with cancer within a year. The study estimated that taking these results into account could lead to an extra six people with undiagnosed cancer being urgently referred for treatment.
A preclinical study led by Weill Cornell Medicine researchers found that the iron-chelating drug deferiprone can selectively target and kill ovarian cancer cells. By starving cancer cells of iron, deferiprone triggers a cellular stress response, prompting the immune system to attack them.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
A landmark study found women with severe endometriosis have a 10-fold increased risk of ovarian cancer, compared to those without the disease. The study analyzed over 78,000 women and revealed that those with severe endometriosis are also at higher risk for type I ovarian cancer.
Researchers at Dana-Farber Cancer Institute have developed CAR memory-like NK cells targeting the mesothelin protein, demonstrating superior antitumor activity in laboratory and animal models. The new cells maintained their effectiveness even after exposure to immunosuppressive ascitic fluid.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
Researchers at Wayne State University aim to develop improved treatments for ovarian cancer by targeting dual-specificity phosphatase 1, a protein involved in drug resistance. The four-year grant will support the study's efforts to improve survival and remission rates.
Research links early menopause to higher risks of breast and ovarian cancer in women. Second-degree relatives also show increased risks for colon, prostate, and testicular cancers.
Researchers found that adding BRCA1 testing to prenatal carrier screening is cost-effective and can identify at-risk individuals before they develop cancer. The study simulated a cohort of pregnant patients and found that this approach could prevent 1,394 breast and ovarian cancer cases and 1,084 fewer deaths.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
This meta-analysis evaluated the diagnostic performance of three-dimensional power Doppler (3DPD) for detecting ovarian cancer in adnexal masses. The results show that 3DPD has good sensitivity and specificity, particularly in complex or suspicious masses. However, it does not add significant value to current 2D US-based approaches.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
A plant virus treatment, composed of cowpea mosaic virus nanoparticles, has shown remarkable success in improving survival rates and suppressing the growth of metastatic tumors across various cancer models. The treatment was effective even after surgical removal of tumors, indicating its potential to prevent metastasis.
A large-scale study of 572 Asian families with BRCA1 and BRCA2 mutations found increased breast cancer risk over time, with highest incidence at age 55. The study provides a new framework for estimating cancer risks in Asian carriers, supporting tailored clinical management approaches.
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
A recent study investigated the causal relationships between sarcopenia-related traits, body mass index (BMI), and ovarian cancer risk. The research found that slower usual walking pace was associated with lower ovarian cancer risk, while high appendicular lean mass and high BMI were linked to increased risk. These findings highlight a...
A new machine learning assay combines cell-free DNA fragment patterns and protein biomarkers to differentiate patients with ovarian cancer from healthy controls. The approach has shown high accuracy in detecting the disease, outperforming current biomarkers.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
A new study from Uppsala University found that women with germ cell tumors have a significantly lower five-year survival rate (85.2%) compared to men (98.2%). The researchers suggest that concentrating patients in fewer hospitals and using treatment strategies for testicular cancer could improve survival rates and reduce side effects.
Researchers at Johns Hopkins Kimmel Cancer Center and University School of Medicine developed an algorithm, REAL-FAST, to identify high-risk precancerous lesions on the fallopian tubes. The test accurately detected cancer 95.8% of the time and correctly ruled out cancer 97.1% of the time.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
A new study published in Oncotarget reveals a higher prevalence of germline BRCA1 and BRCA2 mutations in ovarian cancer patients from the Salento peninsula, with 28.6% having familial cases and 39.7% having sporadic cases. The study found that 29.8% of patients were carriers of BRCA1/2 mutation.
Researchers found that tumors with high levels of stroma are twice as likely to exhibit chemoresistance to conventional treatment. The study aims to utilize a readily obtainable biomarker, TSP, to tailor more effective treatments for patients diagnosed with ovarian cancer.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
A new method reveals genes associated with proteostasis and mRNA surveillance as important for explaining treatment resistance. The approach also identifies DNA repair deficiency as a key factor sensitizing cells to chemotherapy, PARP inhibitors, and NK killing.
Researchers have developed a new urine-based test for early detection of ovarian cancer using nanopore sensing technology. The method can simultaneously identify multiple peptides, including those derived from LRG-1, and shows promise for improving 5-year survival rates by up to 75%.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers found that ovarian cancer cells spread more easily in tissues that are senescent or aged due to the secretion of a unique extracellular matrix. This matrix attracts cancer cells and allows them to attach and spread faster, potentially leading to worse outcomes in older populations.
Researchers developed a training curriculum for community health workers to enhance cancer genetic screening in Black women. The 10-module program, KEEP IT, improved genetic knowledge and competencies among CHWs, who are trusted members of their communities.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
A Wayne State University study reports progress in a therapeutic approach that can restore immune surveillance and provide long-term protection against ovarian cancer tumors. The therapy, CARG-2020, has shown promise in animal models and may prove more effective than existing immunotherapies.
A study of 562,000 women with endometrial, ovarian, or cervical cancer reveals racial and ethnic disparities in clinical trial enrollment. Underrepresented groups face significant barriers to participation, highlighting the need for continued efforts to address these disparities.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Researchers Matthew Sikora and Benjamin Bitler aim to understand the genetic risk factor for ovarian cancer that varies greatly among ethnic communities. The five-year project will focus on a specific genetic variant, rs3820282, which has been linked to various gynecologic diseases.
Researchers at UNC School of Medicine have pieced together the lesser-known DNA repair pathway, polymerase theta-mediated end joining (TMEJ), which is upregulated in patients with hereditary breast cancer, ovarian cancer, and prostate cancer. The discovery could lead to new therapies for cancer by targeting this pathway.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at The Wistar Institute have engineered novel monoclonal antibodies that engage Natural Killer cells through Siglec-7, a conserved glyco-immune marker, to fight against cancer. These new approaches demonstrate preclinical feasibility and potential for treating treatment-resistant ovarian cancers.
A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
A new blood test called OvaPrint TM detects specific nucleic acids in the blood, distinguishing between cancerous and benign pelvic masses with high accuracy. The test has the potential to improve treatment outcomes by identifying the best surgical approach for patients with a pelvic mass.
Researchers have pinpointed the molecular mechanism by which a large portion of BRCA1 mutations cause cancers in women. The study found that the E3 ligase activity of BRCA1 is crucial in several stages of DNA repair and tumor suppression, reinterpreting previous findings.
Researchers developed a low-cost, ultrasensitive blood test to detect a highly specific biomarker for multiple common cancers. The test showed promise for early cancer detection and disease monitoring, detecting levels of the biomarker in the blood of patients with many types of cancers.
A new study by Columbia University Mailman School of Public Health found that women living in more walkable neighborhoods have a lower risk of obesity-related cancers, particularly postmenopausal breast cancer. Neighborhood walkability is associated with increased physical activity and reduced car-dependency.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.